ATBECHDEDKESFRGBGRITLILUNLSEMCPTIE......FI......................................JDIM360 (Ver 1.5 21 Nov 2005) - 1620000/0 1990830/01642975EUROPEAN PATENT APPLICATIONA320060412EP05024209.819961220enenen57596719951220US66139319960607US2006041220061520060405200614C12N 15/12 20060101AFI20060215BHEP C07K 14/705 20060101ALI20060215BHEP C07K 16/28 20060101ALI20060215BHEP C12N 5/20 20060101ALI20060215BHEP deChemokinrezeptoren 88-2B (CKR-3) sowie deren AntikörperenChemokine receptors 88-2B (CKR-3) and their antibodiesfrRécepteurs 88-2B de chémokine (CKR-3) et ses anticorps96945669.8081106319970626ICOS Corporation07306420FB6855A/E11668E22021 20th Avenue S.E.Bothell WA 98201US00000000Gray, Patrick W.1600 40th AvenueSeattle WA 98122USSchweickart, Vicki L.1421 Orange Place NorthSeattle WA 98109USRaport, Carol J.2300 211th Street S.E.Bothell WA 98021USRichardson, Kateet al00080182Forrester & Boehmert, Pettenkoferstrasse 20-2280336 MünchenDEATBECHDEDKESFIFRGBGRIEITLILUMCNLPTSE20060412200615

The present invention provides polynucleotides that encode the chemokine receptors 88-2B and materials and methods for the recombinant production of these chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.